Active Biotech and Ipsen to present Tasquinimod Phase II Overall Survival data at the 2012 ASCO Annual Meeting
(Thomson Reuters ONE) -
Lund (Sweden) and Paris (France), May 18, 2012, Active Biotech (NASDAQ OMX
NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) will present tasquinimod
(TASQ), their prostate cancer drug candidate, at the scientific conference "2012
ASCO Annual Meeting" to be held in Chicago (USA) on 1-5 June 2012. The
presentation will provide overall survival (OS) data from the tasquinimod Phase
II study in chemotherapy-naïve metastatic castrate resistant prostate cancer
(CRPC).
The poster "Tasquinimod and survival in men with metastatic castration-resistant
prostate cancer: Results of long-term follow-up of a randomized phase II
placebo-controlled trial" A.J. Armstrong, M. Häggman, W.M. Stadler, J.R.
Gingrich, V.J. Assikis, J. Polikoff, S.R. Denmeade, D. J. George, C. Andreou,
W.R. Clark, P. Sieber, R. Agajanian, L. Belkoff, J-E. Damber, Ö. Nordle, G.
Forsberg, M. A. Carducci, R. Pili. will be presented on June 4 at 08:00 am CDT
(3:00 pm CET).
The abstract released today, based on 97 events, shows that overall survival
after tasquinimod treatment is longer than previously reported in this patient
population. Median time to death was 34.2 vs. 30.2 months (tasquinimod vs
placebo). A preliminary subgroup analysis using the PCWG2 (Prostate Cancer
Clinical Trials Working Group 2) defined criteria showed that median time to
death in the bone-metastatic subgroup was 34.2 vs. 25.6 months (tasquinimod vs
placebo). The impact of the cross-over design and the imbalance among groups in
favor of placebo will be discussed in the presentation.
For more detailed information, please see www.asco.org.
A global, pivotal, randomized, double-blind, placebo-controlled Phase III study
of tasquinimod in patients with metastatic CRPC is ongoing. The aim of the study
is to confirm tasquinimod's efficacy on the disease, with radiological
Progression Free Survival (PFS) as the primary endpoint and overall survival as
secondary endpoint. The study will include about 1,200 patients in more than
250 clinics. Recruitment is proceeding according to plan with top line results
expected by the end of 2013.
About tasquinimod
Tasquinimod has a pleiotropic mode of action which includes immunomodulatory,
anti-angiogenic and anti-metastatic activity. Today the development of
tasquinimod is principally focused on the treatment of prostate cancer. It was
announced in December 2009 that the primary endpoint of the Phase II clinical
study, to show a higher fraction of patients with no disease progression during
the six-month period of treatment using tasquinimod, had been met. Phase II
results were published in Journal of Clinical Oncology in September 2011. It was
concluded that tasquinimod significantly slowed disease progression and improved
Progression Free Survival (PFS) in chemonaïve patients with metastatic castrate-
resistant prostate cancer (CRPC), alongside an acceptable side effect profile.
Six month progression free proportion of patients for tasquinimod and placebo
treatment groups were 69% and 37%, respectively (p<0.0001), with a median PFS of
7.6 vs. 3.3 months (p=0.0042). Analysis of up to three years safety data from
the Phase II study, presented at the EAU February 2012, show that treatment side
effects were mild to moderate (~ 5% of AEs grade 3-4), manageable and less
frequent after two months of therapy. The adverse events observed included
gastrointestinal disorders, primarily observed initially during treatment,
fatigue and musculoskeletal pain.
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or entering
pivotal phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod
for prostate cancer as well as ANYARA for use in cancer targeted therapy,
primarily of renal cell cancer. In addition, laquinimod is in Phase II
development for Crohn's and Lupus. Further projects in clinical development
comprise the two orally administered compounds, 57-57 for Systemic Sclerosis and
RhuDex(®) for rheumatoid arthritis. Please visit http://www.activebiotech.com
for more information.
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales
exceeding ?1.1 billion in 2011. Ipsen's ambition is to become a leader in
specialty healthcare solutions for targeted debilitating diseases. Its
development strategy is supported by four franchises: neurology / Dysport(®),
endocrinology / Somatuline(®), uro-oncology / Decapeptyl(®) and hemophilia.
Moreover, the Group has an active policy of partnerships. R&D is focused on
innovative and differentiated technological patient-driven platforms, peptides
and toxins. In 2011, R&D expenditure totaled more than ?250 million, above 21%
of Group sales. The Group has total worldwide staff of close to 4,500 employees.
Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN
code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD").
The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level
I American Depositary Receipt (ADR) program, which trade on the over-the-counter
market in the United States under the symbol IPSEY. For more information on
Ipsen, visit www.ipsen.com.
Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are
based on the Group's management strategy, current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may cause
actual results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect the Group's future
ability to achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today.
Moreover, the targets described in this document were prepared without taking
into account external growth assumptions and potential future acquisitions,
which may alter these parameters. These objectives are based on data and
assumptions regarded as reasonable by the Group. These targets depend on
conditions or facts likely to happen in the future, and not exclusively on
historical data. Actual results may depart significantly from these targets
given the occurrence of certain risks and uncertainties, notably the fact that a
promising product in early development phase or clinical trial may end up never
being launched on the market or reaching its commercial targets, notably for
regulatory or competition reasons. The Group must face or might face competition
from Generics that might translate into loose of market shares.
Furthermore, the Research and Development process involves several stages each
of which involve the substantial risk that the Group may fail to achieve its
objectives and be forced to abandon its efforts with regards to a product in
which it has invested significant sums. Therefore, the Group cannot be certain
that favorable results obtained during pre-clinical trials will be confirmed
subsequently during clinical trials, or that the results of clinical trials will
be sufficient to demonstrate the safe and effective nature of the product
concerned. The Group also depends on third parties to develop and market some of
its products which could potentially generate substantial royalties; these
partners could behave in such ways which could cause damage to the Group's
activities and financial results. The Group expressly disclaims any obligation
or undertaking to update or revise any forward looking statements, targets or
estimates contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such statements are based,
unless so required by applicable law.
The Group's business is subject to the risk factors outlined in its registration
documents filed with the French Autorité des Marchés Financiers.
For further information:
Active Biotech
Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95
tomas.leanderson(at)activebiotech.com
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Ipsen
Media
Didier Véron
Vice President, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
E-mail: didier.veron(at)ipsen.com
Financial Community
Pierre Kemula Stéphane Durant des Aulnois
Vice President, Investor Investor Relations Manager
Relations Tel.: +33 (0)1 58 33 60 09
Tel.: +33 (0)1 58 33 60 08 Fax: +33 (0)1 58 33 50 63
Fax: +33 (0)1 58 33 50 63 E-mail: stephane.durant.des.aulnois(at)ipsen.com
E-mail: pierre.kemula(at)ipsen.com
Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 08:30 a.m. CET on May 18, 2012.
Active Biotech and Ipsen to present Tasquinimod Phase II OS data:
http://hugin.info/1002/R/1612953/513587.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1612953]
Unternehmensinformation / Kurzprofil:
Datum: 18.05.2012 - 08:31 Uhr
Sprache: Deutsch
News-ID 148022
Anzahl Zeichen: 11028
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 242 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech and Ipsen to present Tasquinimod Phase II Overall Survival data at the 2012 ASCO Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
